Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity

• Status: Completed
• Trial end date: 2017-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult population suffers the disease.

Banaba has shown evidence that has on metabolic syndrome, insulin sensitivity and insulin secretion.

The investigators hypothesis was that the the administration of resveratrol modifies the metabolic syndrome, insulin sensitivity and insulin secretion.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Guadalajara
• Treatments: Insulin; Insulin, Globin Zinc; Magnesium Oxide

Criteria

Inclusion Criteria:

• Patients both sexes,

• Age between 30 and 60 years,

• Metabolic Syndrome according to the IDF criteria

• Waist circumference

• Man ≥90 cm

• Woman ≥80 cm

And two of the following criteria:

• High density lipoprotein

• Man ≤40 mg/dL

• Woman ≤50 mg/dL

• Fasting glucose ≥100 mg/dL

• Triglycerides ≥150 mg/dL

• Blood pressure ≥130/85 mmHg

• Informed consent signed

Exclusion Criteria:

• Women with confirmed or suspected pregnancy

• Women under lactation and/or puerperium

• Hypersensibility to resveratrol

• Physical impossibility for taking pills

• Known uncontrolled renal, hepatic, heart or thyroid diseased

• Previous treatment for the metabolic syndrome components

• Body Mass Index ≥39.9 kg/m2

• Fasting glucose ≥126 mg/dL

• Triglycerides ≥500 mg/dL

• Total cholesterol ≥240 mg/dL

• Low density lipoprotein (c-LDL) ≥190 mg/dL

• Blood Pressure ≥140/90 mmHg